TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price53.62 USD
Fair value67.29
Ethical score70.0/100
Our investment reviews on this name
2026-09-14Read Accumulation53.89-0.5% to today
2026-08-14Read Distribution49.55+8.2% to today
2026-07-02Read Markup49.52+8.3% to today ✓
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
TG Therapeutics, Inc. holds its Markdown at $53.62. Elevated stress, defensive posture warranted, held for 15 days.
As held on the ledger · 2026-10-01
Phase
Markdown · caution
Quantitative state
Elevated stress, defensive posture warranted, held for 15 days
Price at the screen
$53.62
Valuation
19.57 trailing · 19.80 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.66
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
23.86%
Below 33%
Interest-bearing debt is just 23.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
5.91%
Below 33%
Cash held in interest-bearing accounts and securities is 5.9% of assets, under the one-third limit.
Pass
Receivables
36.19%
Below 49%
Money owed to the company is 36.2% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
TG Therapeutics, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 24%, inside the ~33% line, and almost none of its income is interest, so it passes.
Read as at 2026-10-07. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-01 screen. The gold marker is the market price at the same screen. A 25.5% margin of safety to the base estimate.
Third-party analyst targets: 7 covering, consensus Strong Buy. The average target sits +40% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-01 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
New Drug Launch Fuels Biotech Profit Surge
A fresh treatment for B cell diseases has reached patients and revenue is already surging seventy percent. The business posts a sixty six percent profit margin alongside one hundred thirteen percent return on equity, all while the shares sit on a forward multiple of sixteen point seven times. Ethical screens clear and the analyst group calls buy with a sixty dollar median target above the current fifty four eighty seven price.
Our fair value sits modestly higher at sixty six yet the opportunity rating remains none. An unknown moat leaves open questions about how durable those margins will prove against larger rivals in the same field. Strong numbers on paper do not automatically create a standout case when competitive staying power stays unproven.
Drug launches carry real commercial and regulatory risks even after initial success, and any setback can cut earnings sharply. The setup shows clear financial strength but lacks the edge that would lift it into a higher conviction idea. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
TGTX trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Accumulation$53.62-0.5%Entry 6
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it buy, with a mean price target of $48. Insiders have been net sellers over the past quarter.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it buy, with a mean price target of $48.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 0.1% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it buy, with a mean price target of $48.
2026-07-18Markup$49.52+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 18%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (7 analysts) rates it buy, with a mean price target of $48.
2026-07-03Markup$49.52+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Markup$49.52Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
